These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28759653)

  • 1. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
    Misbah SA
    J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic indications of intravenous immunoglobulins].
    Tellier Z; Mouthon L
    Transfus Clin Biol; 2003 Jun; 10(3):179-84. PubMed ID: 12798854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.
    Bayry J; Misra N; Latry V; Prost F; Delignat S; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Clin Biol; 2003 Jun; 10(3):165-9. PubMed ID: 12798851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies].
    Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K
    Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
    Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms of immunoglobulins activity].
    Kowalczyk D
    Pol Merkur Lekarski; 2011 Jun; 30(180):397-9. PubMed ID: 21751546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.
    Kaveri SV; Maddur MS; Hegde P; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):2-5. PubMed ID: 21466545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG in autoimmune disease - Potential next generation biologics.
    Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
    Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
    Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
    Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
    Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
    Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of intravenous immunoglobulins in the treatment of primary immunodeficiencies].
    Lewandowicz-Uszyńska A; Jankowski A
    Pol Merkur Lekarski; 2011 Jun; 30(180):409-12. PubMed ID: 21751549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga
    Mersich C; Ahrer K; Buchacher A; Ernegger T; Kohla G; Kannicht C; Pock K; Römisch J
    Biologicals; 2017 Jan; 45():33-38. PubMed ID: 28341308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.